Product category:
Laboratory and scientific professional organisations
News Release from: Cancer Research UK | Subject: CRC-CT
Edited by the Laboratorytalk Editorial
Team on 30 January 2007
Australian cooperation in cancer therapy
Seven of Australia's leading research organisations plus Cancer Research Technology, Bionomics, and Millipore/Chemicon, are forming the Cooperative Research Centre for Cancer Therapeutics (CRC-CT)
The centre will be funded by an award of A$37.6 million from the Australian federal government and further contributions from the participants totalling $148 million to create a world-class translational research organisation headquartered at the Walter and Eliza Hall Institute, Biotechnology Centre, Melbourne, Victoria CRC-CT will be dedicated to the discovery and development of novel small molecules for targeted cancer therapies
This article was originally published on Laboratorytalk on 10 Dec 2003 at 8.00am (UK)
Related stories
New test could prevent more cervical cancer
A new test could be a more effective early warning system for preventing cervical cancer than the traditional smear according to Cancer Research UK scientists
Secrets of rogue cancer molecule revealed
Findings will help accelerate the search for potent and specific drugs that can target the protein and stop the growth and spread of these cancers
CRC-CT is funded for seven years and brings together Australia's foremost expertise in cancer biology, translational oncology and drug discovery to produce high-quality novel drug candidates for further development and commercialisation.
Professor Dick Fox, chairman-elect of CRC-CT and a medical oncologist said: "With cancer killing more Australians than any other single cause there is an urgent need for more effective therapies.
"Australia invests over $150 million each year in cancer research and the creation of CRC-CT provides a catalyst for translation into new therapies through bringing together immense knowledge, expertise, and resources to realise the therapeutic potential in the outstanding research being carried out at Australian research institutes.
Further reading
Pioneering RNA interference library completed
Two charities have produced the world's first cancer-focussed RNA interference library - a collection of 23,742 designer molecules, created to inactivate a total of 7914 human genes
Another step closer to cracking cancer
The origin of a cancer which is common in people with HIV or who have had an organ transplant, Kaposi sarcoma, points way to possible future therapy
Microscopic envelopes deliver drug to tumours
Molecular envelopes could be used to deliver an anticancer drug to tumours with fewer side effects than the drug alone, a report in the British Journal of Cancer reveals this week
"CRC-CT will benefit enormously from the experience and track record of Cancer Research Technology in developing and commercialising cancer therapies, and in fact our goal is to use this experience to develop a sustainable development and commercialisation company for cancer therapeutics to benefit Australians in the long term".
CRC-CT will draw on significant investments already made in drug discovery infrastructure in Victoria, Queensland and South Australia.
Organisations participating in CRC-CT include:.
Bio21 Australia, Melbourne.
Bionomics, Adelaide.
Cancer Council of Victoria, Melbourne.
Cancer Research Technology, London.
CSIRO Molecular Health Technologies, Melbourne.
Griffith University, Brisbane.
Millipore/Chemicon, Sydney.
Monash University / Victorian College of Pharmacy, Melbourne.
Peter MacCallum Cancer Research Centre, Melbourne.
St Vincent's Research Institute, Melbourne.
Walter and Eliza Hall Institute, Melbourne.
CRC-CT will build on the founding participant's considerable intellectual property and engage broadly with Australian public sector research organisations and companies to develop new therapies for treating cancer in four critical areas:.
Disrupting blood vessels that feed cancers.
Preventing cancer cells invading other parts of the body.
Adjunct treatments to minimise the side effects of chemo- and radio-therapies.
Overcoming resistance of tumours to chemotherapies.
Keith Blundy, chief operating officer of Cancer Research Technology said, "We are extremely pleased to provide CRC-CT with a strong route to market through our extensive experience in collaborating with academic researchers.
"By expanding our extensive network of leading cancer scientists and commercial partners in Europe and the US to include Australia, we look forward to developing a strong capability in Australia to benefit cancer sufferers globally.".
• Cancer Research UK: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
